Novo Nordisk’s partnership with CVS Caremark designed to help patients with high out-of-pocket costs
The Endocrine Society applauded Novo Nordisk’s recent partnership with CVS Caremark on their new program Reduced Rx™, a prescription savings program that offers discounts on certain medications. Through the partnership, which goes into effect today, patients facing high out-of-pocket costs for insulin will be able to purchase human insulin, Novolin®, for $25 per 10 mL vial, a potential savings of $100 for cash-paying patients.
People with type 1 diabetes are unable to produce their own insulin and need insulin treatment to maintain their glucose control. People with the more common type 2 diabetes do not produce enough insulin or their bodies cannot use it efficiently. These individuals may need insulin treatment as well. Many people with diabetes depend on insulin, yet increasing prices create a dangerous barrier to access this critical therapy.
The Society is encouraged by Novo Nordisk’s efforts to increase affordable access to this life-saving therapy and will continue to strongly advocate for people with diabetes who depend on insulin to treat their condition.
The Society believes that with greater transparency across the insulin supply chain, stakeholders can work together to make drug pricing more predictable, reduce out-of-pocket costs, and help patients and providers maintain access to affordable, patient-centered therapies.
About the Endocrine Society
Endocrinologists are at the core of solving the most pressing health problems of our time, including diabetes, obesity, infertility, bone health, and hormone-related cancers. The Endocrine Society is the largest global organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
With more than 18,000 members in 133 countries, the Society serves as the voice of the endocrine field. Through its renowned journals and ENDO, the world's largest endocrine meeting, the Society accelerates hormone research, advances clinical excellence in endocrinology, and advocates for evidence-based policies on behalf of the global endocrine community. To learn more, visit our online newsroom.
Colleen Williams Associate Director, Communications and Media Relations Phone: (202)-971-3611 [email protected]
Jenni Glenn Gingery Director, Communications and Media Relations Phone: (202)-971-3655 [email protected]
